Skip to content

Clinical trials

Phase 1/2 Prostatic Neoplasms trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Prostatic Neoplasms Phase: Phase 1/2 Clear all

389 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20004
20016
20027
20036
200412
200515
200617
20077
200812
200913
201017
20118
201212
201314
20149
201513
201613
201712
201819
201915
202017
202114
202215
202317
202423
202526
202631

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed166
Recruiting74
Terminated62
Unknown status32
Active, not recruiting29
Not yet recruiting13
Withdrawn11
Suspended1
Enrolling by invitation1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Cancer Institute (NCI)15
Memorial Sloan Kettering Cancer Center13
AstraZeneca10
M.D. Anderson Cancer Center7
Cell Genesys6
Millennium Pharmaceuticals, Inc.6
Sunnybrook Health Sciences Centre6
University Health Network, Toronto6
First Affiliated Hospital of Fujian Medical University5
Jiangsu HengRui Medicine Co., Ltd.5

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Prostatic Neoplasms389
Breast Neoplasms43
Neoplasms33
Ovarian Neoplasms33
Neoplasm Metastasis31
Pancreatic Neoplasms26
Carcinoma, Non-Small-Cell Lung24
Colorectal Neoplasms18
Stomach Neoplasms17
Urinary Bladder Neoplasms17

Trials

Showing 76 to 100 of 389. Each trial links to its page on Pharma Observatory.

289 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.